MJA
MJA InSight
MJA Careers
Editorials

Ensuring the safety of new medications and devices: are naltrexone implants safe?

Alex D Wodak, Robert Ali, David Henry and Lloyd Sansom
Med J Aust 2008; 188 (8): 438-439.

Naltrexone implants have not been subject to the usual rigorous scrutiny required for new devices in Australia, but are widely used through the Special Access Scheme

Alex D Wodak, FRACP, Director1
Robert Ali, FAChAM, Associate Professor2
David Henry, FRCP(Edin), Adjunct Professor3
Lloyd Sansom, AO, PhD, Emeritus Professor4
1 Alcohol and Drug Service, St Vincent’s Hospital, Sydney, NSW.
2 Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA.
3 School of Medicine and Public Health, University of Newcastle, Newcastle, NSW.
4 Division of Health Science, University of South Australia, Adelaide, SA.
Article References: 
Reference Text: 
Lintzeris N, Lee S, Scopelliti L, et al. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Med J Aust 2008; 188: 441-444.
Reference Order: 
1
PubMed ID: 
Reference Text: 
Roozen HG, de Waart R, van der Windt DA, et al. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 2006; 16: 311-323.
Reference Order: 
2
PubMed ID: 
16361086
Reference Text: 
Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence (Cochrane review). The Cochrane Library, Issue 1, 2006. Oxford: Update Software.
Reference Order: 
3
PubMed ID: 
Reference Text: 
Kirchmayer U, Davoli M, Verster AD, et al. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Review Addiction 2002; 97: 1241-1249.
Reference Order: 
4
PubMed ID: 
Reference Text: 
Mattick RP, Digiusto E, Doran CM, et al. National evaluation of pharmacotherapies for opioid dependence: report of results and recommendations. Sydney: National Drug and Alcohol Research Centre, 2004.
Reference Order: 
5
PubMed ID: 
Reference Text: 
Tattersall M, for the Australian Drug Evaluation Committee (ADEC). ADEC 200th meeting recommendations. Canberra: Therapeutic Goods Administration, 1999. http://www.tga.gov.au/docs/html/adec/adec0200.htm (accessed Jan 2008).
Reference Order: 
6
PubMed ID: 
Reference Text: 
Digiusto E, Shakeshaft A, Ritter A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004; 99: 450-460.
Reference Order: 
7
PubMed ID: 
15049745
Reference Text: 
Barnao T. I woke up ... cured of heroin. Australian Women's Weekly 1997; July: 31-34.
Reference Order: 
8
PubMed ID: 
Reference Text: 
Shanahan MD, Doran CM, Digiusto E, et al. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict Behav 2006; 31: 371-387.
Reference Order: 
9
PubMed ID: 
15972245
Reference Text: 
US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Naltrexone for extended-release injectable suspension for treatment of alcohol dependence. Substance Abuse Treatment Advisory 2007; 6 (1). http://kap.samhsa.gov/products/manuals/advisory/text/0701_naltrexone.htm (accessed Jan 2008).
Reference Order: 
10
PubMed ID: 
15972245
Reference Text: 
Department of Health and Ageing. Therapeutic Goods Administration. Special Access Scheme at a glance. http://www.tga.gov.au/hp/sasglance.htm (accessed Mar 2008).
Reference Order: 
11
PubMed ID: 
Reference Text: 
Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006; 82 Suppl 3: iii56-iii63. doi:10.1136/sti.2005.019273.
Reference Order: 
12
PubMed ID: 
Reference Text: 
Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-218.
Reference Order: 
13
PubMed ID: 
16461865

The full contents of this page are only available to subscribers.